Abstracts tagged "gout"

Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Brian LaMoreaux¹, Chelsea McKibbon², Katie Obermeyer¹, Lissa Padnick-Silver¹, Gerald Smith², Jiaxuan Wang² and Haridarshan Patel¹, ¹Horizon Therapeutics, Deerfield, IL, ²Cytel Inc., Vancouver, BC, Canada
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…
Abstract Number: 1888 • ACR Convergence 2023
Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy
Wan-Hee Yoo¹, Eun Hae Park¹, Dae-Woo Lee¹, Riel Casto-Zunti² and Yunjung Choi¹, ¹Jeonbuk National University Medical School, Jeonju, South Korea, ²University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: In a recent study, the low specificity of Dual-Energy CT (DECT) has raised concerns due to the frequent occurrence of pseudo lesions, also referred…
Abstract Number: 0237 • ACR Convergence 2023
Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
Lissa Padnick-Silver¹, Andrew Concoff², Hong-Ye Gao¹, Qianhong Fu¹, Brian LaMoreaux¹ and N. Lawrence Edwards³, ¹Horizon Therapeutics, Deerfield, IL, ²United Rheumatology, Happauge, NY, ³University of Florida College of Medicine, Gainesville, FL
Background/Purpose: Pegloticase, a recombinant pegylated uricase, rapidly reduces serum urate (SU) in patients refractory to/intolerant of oral urate-lowering therapies (ULTs).1,2 However, pegloticase is generally used…
Abstract Number: 0753 • ACR Convergence 2023
Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System
Jeremy Sullivan¹, Anna Ware², Gary Tarasovsky³, Cherish Wilson⁴, Mary Whooley³, Jasvinder Singh⁵, Jinoos Yazdany⁶ and Gabriela Schmajuk⁴, ¹University of California San Francisco, San Francisco, CA, ²Palo Alto VA, Minneapolis, MN, ³San Francisco VA, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA
Background/Purpose: New guidelines published in 2020 conditionally recommend HLA-B*58:01 allele testing for South Asian and Black patients receiving allopurinol to reduce the risk of severe…
Abstract Number: 1109 • ACR Convergence 2023
Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Blanka Stiburkova¹, Katerina Pavelcova², Jana Masinova¹, Marketa Pavlikova³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Praha 2, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
Abstract Number: 1909 • ACR Convergence 2023
Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease
Lena Eder¹ and David Leverenz², ¹Duke University, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC
Background/Purpose: Patients with gout and chronic kidney disease (CKD) are often not appropriately managed with goal-directed urate-lowering therapy (ULT). To address deficits in management of…
Abstract Number: 0238 • ACR Convergence 2023
Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature
Ellen Prendergast¹, Nicola Dalbeth², David Bursill³, Chris Frampton⁴ and Lisa Stamp⁴, ¹Te Whatu Ora Southern, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Royal Adelaide Hospital, Kensington Gardens, Australia, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: Uniform terminology with standardised definitions for the various elements and states of a disease ensure accurate and consistent technical communication. In 2019 the Gout…
Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Natalie McCormick¹, Chio Yokose², Jie Wei³, Na Lu⁴, Deborah Wexler¹, Mary De Vera⁵, J. Antonio Avina-Zubieta⁴, Yuqing Zhang⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁷Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Roy Fleischmann¹, James Cheng-Chung Wei², Zancong Shen³, sarah Morris⁴, Elizabeth Polvent⁵, Andrea Clouser-Roche⁴, Vijay Hingorani⁶, Rongzi Yan⁷, Shunqi Yan⁸, Robert Keenan⁹ and Li-Tain Yeh¹⁰, ¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ³Arthrosi Therapeutics, San Diego, CA, ⁴Arthrosi Therapeutics Inc, San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Vanguard Healthsciences, Inc., San Diego, CA, ⁷Arthrosi Therapeutics, Inc, Irvine, CA, ⁸Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC, ¹⁰Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…
Abstract Number: 2428 • ACR Convergence 2023
Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Natalie McCormick¹, Kehuan Lin², Chio Yokose³, Na Lu⁴, Yuqing Zhang¹ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…
Abstract Number: 0222 • ACR Convergence 2022
Primary Care Provider Utilization of Musculoskeletal Ultrasound for the Diagnosis of Acute Gout Flares: A Novel Opportunity for Rheumatology-Focused Educational Curricula
Wes Cubberley¹, Taylor Nelson¹, Michael Battistone², Andrea Barker², Jeremy Timm³, Anthony Minjarez² and Gary Kunkel¹, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA, Salt Lake City
Background/Purpose: Gout, the most common inflammatory arthritis, can be challenging to identify, especially when clinical criteria are insufficient to support a diagnosis. Musculoskeletal ultrasound (MSK…
Abstract Number: 1787 • ACR Convergence 2022
The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study
Puja Khanna¹ and Ryan Beal², ¹University of Michigan, Ann Arbor, MI, ²Dyve Biosciences, Inc, Camarillo, CA
Background/Purpose: Inflammatory cytokine-mediated bone resorption increases serum calcium (Ca2+) and can lead to calcification at chronically inflamed sites. Ca2+ influences cytokine activity to intensify the…
Abstract Number: 1806 • ACR Convergence 2022
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
Naomi Schlesinger¹, Lissa Padnick-Silver², Katie Obermeyer² and Brian LaMoreaux², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…

« Previous Page
1
…
8
9
10
11
12
…
45
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].